Abstract
Objectives:
Migrainous vertigo (MV) is accepted as a common cause of episodic vertigo. The peripheral or central vestibular localization of the deficit as well as the pathophysiology is unclear. This retrospective study was designed to assess the clinical features and treatment outcomes of MV.
Methods:
132 patients with MV were studied. Comprehensive neurological tests were performed and pure tone audiometry, caloric test, vestibular evoked myogenic potential (VEMP), and posturography were also conducted. For medical management, sibelium, amitryptilin, and topamax were tried.
Results:
31% of patients reported cochlear symptoms including hearing disturbance, tinnitus, earfullness during MV symptom, and 41% showed head-shaking nystagmus. Caloric test results revealed unilateral caloric hypofunction in 23%, and 29% showed VEMP asymmetry. Posturography results revealed vestibular dysfunction in 24%.Symptom relief was experienced in 55% with flunarizine, 33% with amitriptyline, and 9% with topiramate.
Conclusions:
MV demonstrated various clinical features, however, this disease can be treated well by medical management.
Get full access to this article
View all access options for this article.